WO2025253319 - POLYENE MACROLIDE FOR USE IN METHODS FOR TREATMENT OF FUNGAL INFECTIONS
National phase entry is expected:
Publication Number
WO/2025/253319
Publication Date
11.12.2025
International Application No.
PCT/IB2025/055772
International Filing Date
04.06.2025
Title **
[English]
POLYENE MACROLIDE FOR USE IN METHODS FOR TREATMENT OF FUNGAL INFECTIONS
[French]
MACROLIDE DE POLYÈNE DESTINÉ À ÊTRE UTILISÉ DANS DES MÉTHODES DE TRAITEMENT D'INFECTIONS FONGIQUES
Applicants **
BIOSERGEN AS
Inventors
OLESEN, Tine Kold
ANDERSEN, Peder Møller
ANDES, David
Priority Data
63/656,281
05.06.2024
US
63/667,940
05.07.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4807 | |
| EPO | Filing, Examination, Granting | 75716 | |
| Japan | Filing, Examination, Granting | 4407 | |
| South Korea | Filing, Examination, Granting | 6528 | |
| USA | Filing, Examination, Granting | 25790 |
Total:
117,248
Contact Us
Abstract[English]
This invention relates to pharmaceutical compositions and methods featuring dosing regimens of Compound 1, or a pharmaceutical acceptable salt or neutral form thereof (e.g., Compound 1 acetate).[French]
La présente invention concerne des compositions pharmaceutiques et des méthodes comprenant des schémas posologiques du composé 1, ou d'un sel pharmaceutiquement acceptable ou d'une forme neutre de celui-ci (par exemple, l'acétate du composé 1).